Suppression of alloreactivity by increasing the dose of donor BMCs. C57BL/6 mice were treated with anti-CD40L mAb in combination with 106 (n = 6), 107 (n = 6), or 108 (n = 6) BALB/c BMCs at day 0. At day 28 an in vivo cytotoxicity assay was performed and peripheral-blood samples were collected 3 days later for FACS analysis. The mice treated with anti-CD40L mAb and 106 BALB/c BMCs eliminated 98.1% ± 1.3% of the CFSE-labeled BALB/c cells within 3 days. The mice treated with anti-CD40L mAb and 107 BALB/c BMCs eliminated 92.5% ± 3.8% of the BALB/c cells within 3 days, whereas no significant elimination of CFSE-labeled donor cells was detected (0.0% ± 6.8% within 3 days) in the group treated with anti-CD40L mAb and 108 BALB/c BMCs. The displayed histograms are representative of each group.
